Achillion Pharmaceuticals

INVESTORS

Press Releases

 
Press Releases
  Date Title View
May 9, 2007
NEW HAVEN, Conn., May 9, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc., (Nasdaq: ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter ended March 31, 2007. For the first quarter of 2007...
PDF
Apr 16, 2007
NEW HAVEN, Conn., April 16, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced the presentation of data validating the clinical antiviral activity of one of Achillion's NS4A antagonists, ACH-806, for the treatment of hepatitis C virus (HCV) infection at the 42nd Annual Meeting of th...
PDF
Mar 27, 2007
NEW HAVEN, Conn., March 27, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc., (Nasdaq: ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter and year ended December 31, 2006. For the full y...
PDF
Mar 21, 2007
NEW HAVEN, Conn., March 21, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) expects to release its results for the fourth quarter and year ended December 31, 2006 after the market closes on Tuesday, March 27, 2007. The company will host a conference call to discuss the results at 4:30 PM ET ...
PDF
Mar 20, 2007
NEW HAVEN, Conn., March 20, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc., (Nasdaq: ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will present a corpo...
PDF
Feb 26, 2007
NEW HAVEN, Conn., Feb 26, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc., (Nasdaq: ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will be presenting a c...
PDF
Feb 8, 2007
FOSTER CITY, Calif. and NEW HAVEN, Conn., Feb 08, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Gilead Sciences (Nasdaq: GILD) and Achillion Pharmaceuticals (Nasdaq: ACHN) today announced their decision to discontinue the development of GS 9132, also known as ACH-806, for the treatment of hepatitis C viral (HCV) infection, based upon preli...
PDF
Feb 5, 2007
NEW HAVEN, CT, February 5, 2007 — Achillion Pharmaceuticals, Inc. today announced that John C. Pottage, M.D., Achillion's Chief Medical Officer, will participate in a panel discussion on Monday, February 12 at the 2007 BIO CEO and Investor Conference in New York City. The panel is a Therapeutic Workshop scheduled for 3:30PM entitled, "Novel H...
PDF
Nov 8, 2006
NEW HAVEN, Conn., Nov 08, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced that it closed the sale of an additional 675,000 shares of its common stock in connection with the exercise of the over-allotment option granted to the underwriters of its recent initial public offering of ...
PDF
Oct 26, 2006
New Haven, Conn., Oct 26, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced the pricing of its initial public offering of 4,500,000 shares of its common stock at $11.50 per share, before underwriting discounts and commissions. All of the common stock is being offered by Achillion. ...
PDF
FirstPrevious
...
25
NextLast